Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
10.28% $4.40
America/New_York / 16 aug 2023 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 8.98 mill |
EPS: | -7.11 |
P/E: | -0.619 |
Earnings Date: | Nov 12, 2023 |
SharesOutstanding: | 2.04 mill |
Avg Daily Volume: | 0.0478 mill |
RATING 2023-10-09 |
---|
B |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Strong Buy | |
Return On Equity: | Sell | |
Return On Asset: | Sell | |
DE: | Sell | |
P/E: | Neutral | |
Price To Book: | Sell |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
2/22 | 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | |
Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Gr.Profit | n/a | n/a | n/a | n/a | n/a | n/a |
Ebit | ||||||
Asset | ||||||
Debt | n/a | n/a | n/a | n/a | n/a | n/a |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -0.619 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.11x |
Company: PE -0.619 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
N/A |
N/A |
Expected Trading Range (DAY) |
---|
$ 6.39 - 6.81 ( +/- 3.24%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-11-20 | Tanner John William | Buy | 32 000 | Stock Option (Right to Buy) |
2023-11-09 | Gregoire Sylvie | Sell | 10 000 | Common Stock |
2023-11-09 | Alam John J | Sell | 12 500 | Common Stock |
2023-09-15 | Cobuzzi Robert Joseph Jr. | Buy | 16 000 | Stock Option (Right to Buy) |
2023-09-15 | Tanner John William | Buy | 16 000 | Stock Option (Right to Buy) |
INSIDER POWER |
---|
44.87 |
Last 93 transactions |
Buy: 1 964 449 | Sell: 147 821 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $4.40 (10.28% ) |
Volume | 0.349 mill |
Avg. Vol. | 0.0478 mill |
% of Avg. Vol | 730.87 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
Diffusion Pharmaceuticals Inc., a biopharmaceutical company, develops novel therapies that enhance the body's ability to deliver oxygen. Its lead product candidate is Trans Sodium Crocetinate that is developed to enhance the diffusion of oxygen to tissues, as well as to treat COVID-19 disease. Diffusion Pharmaceuticals Inc. was founded in 2001 and is based in Charlottesville, Virginia.